Seirbhís Aisíoca Príomhchúraim
Bealach amach 5 an M50, Án Bóthar Thuaidh, Fionnghlas, Baile Átha Cliath 11, D11 XKF3
Guthán: 01 8647100

Primary Care Reimbursement Service
Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3
Tel: 01- 8647100

David Cullinane, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

20th July 2022

PQ: 35336/22

To ask the Minister for Health the number of rapid review dossiers submitted to the HSE from 2016 to date, broken down by the number of dossiers presented that were successful and unsuccessful in the medicines contained in the dossiers being added to the reimbursement scheme; and if he will make a statement on the matter. -David Cullinane

Dear Deputy Cullinane,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 35336/22), which you submitted to the Minister for Health for response.

Information on reimbursement of medicines included under the Community Drug Schemes and under High Tech Drug Arrangements is available from the Primary Care Reimbursement Service (PCRS) website. The reimbursement list does not detail the licensed or approved indication for each medicine included. An update on the reimbursement list is published towards the end of each month and will include relevant changes including new additions for reimbursement under the schemes. For a new addition (i.e. approval) to be included on this update the applicant must have liaised with PCRS to confirm the launch of the product. The update and reimbursement list is accessible on the PCRS website:
https://www.hse.ie/eng/staff/pcrs/online-services/
https://www.sspcrs.ie/libr/html/monthlyproductupdate.pdf

A submission of a rapid review dossier is required by the HSE as part of the pricing and reimbursement process in place for new medicines, as set out in its framework agreement with Industry and which is in place to enable the HSE to comply with its statutory responsibilities under the Health (Pricing and Supply of Medical Goods) Act 2013. Applications for new chemical entities, new innovative formulations and proposed new uses of existing medicines (i.e. license extensions) are triaged through the rapid review process to establish if a HTA is required to determine comparative effectiveness and cost effectiveness. A submission of a rapid review dossier to the HSE is not exclusively reserved for new chemical entity medicines or new uses of existing medicines and may be requested for

example if a price premium over relevant comparator products is being proposed. The number of a rapid review assessment reports received from the National Centre for Pharmacoeconomics (NCPE) following commissioning by the HSE Corporate Pharmaceutical Unit (CPU) is outlined in the table below.

Year	Commissioned Rapid review reports received from NCPE
2016	50
2017	67
2018	48
2019	55
2020	63
2021	70
2022 @ 1st July	53

The National Centre for Pharmacoeconomics (NCPE) publishes details on medicines where the HSE CPU has commissioned a rapid review assessment on their website. The NCPE detail the assessed indication for each medicine listed. The website is updated at regular intervals and includes assessment outcomes and updates on reimbursement for each individual medicine and indication listed: https://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/

Yours sincerely,

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service